Abstract. Predominant T helper (Th)2 and impaired Th1 cell polarization has a crucial role in the development of asthma. Cluster of differentiation (CD)38 is associated with the increased release of interleukin (IL)-12 from dendritic cells (DCs) and DC-induced Th1 cell polarization. However, whether CD38 expression affects DC function in asthma development remains unknown. In the current study, adenoviruses were constructed containing the murine CD38 gene. Overexpression of CD38 protein level in DCs induced from bone-marrow derived DCs (BMDCs) by recombinant mouse granulocyte macrophage colony-stimulating factor and IL-4 was achieved through 24 h adenovirus infection. The results demonstrated that BMDCs with CD38 overexpression exhibited no phenotypic change; however, following stimulation with lipopolysaccharide (LPS), maturation and IL-12 secretion were increased. In addition, CD38-overexpressing BMDCs stimulated with LPS exhibited more effective Th1 cell differentiation. Mice that were administered CD38-overexpressing BMDCs exhibited milder symptoms of asthma. Furthermore, decreased IL-4, IL-5 and IL-13 levels were detected in bronchoalveolar lavage fluid (BALF), reduced immunoglobulin E levels were measured in the sera, and increased interferon-γ was detected in BALF from the recipients of CD38-overexpressing BMDCs. Increased phosphorylated-p38 expression was also detected in LPS-stimulated CD38-overexpressing BMDCs, whereas pretreatment with a p38-specific inhibitor was able to abolish the effects of LPS stimulation and CD38 overexpression on IL-12 release and Th1 cell differentiation in BMDCs. These results suggested that CD38 may be involved in the DC function of alleviating asthma via restoration of the Th1/Th2 balance, thus providing a novel strategy for asthma therapy.
Introduction
The incidence of asthma remains high worldwide. As a chronic airway inflammatory disease, asthma not only harms patient's physical and mental health, but is also considered a burden to society (1, 2) . There are several clinical interventions used to treat asthma, including traditional treatment with glucocorticoids; however, the effects of treatment are not always satisfactory. Glucocorticoid therapy is an effective treatment for asthma; however, its side effects greatly constrain clinical applications (3) . Therefore, it is necessary to explore novel therapeutic strategies for the treatment of asthma.
Various cells, including eosinophils, basophils and cluster of differentiation (CD)4 + T cells, and several proinflammatory mediators, such as tumor necrosis factor-α and interleukin (IL)-17, are involved in the chronic respiratory inflammatory responses of asthma (4, 5) . However, the mechanism underlying asthma remains largely unknown. CD4 + T cells are critical cellular mediators of asthma and inflammation. The CD4 + T cell subset can be divided into T helper (Th)1 and Th2 cells, according to the type of cytokines they release and their function (6) . The impaired balance of Th1/Th2, and the abnormal polarization of Th2 are considered the most important CD38 gene-modified dendritic cells inhibit murine asthma development by increasing IL-12 production and promoting Th1 cell differentiation mechanisms of asthma (7) . During the development of asthma, Th2 cells orchestrate the inflammatory microenvironment via the production of Th2 cytokines (IL-4, IL-5 and IL-13), thus contributing to the pathological process of asthma (8) . The balance between Th1 and Th2 cells is finely tuned and their differentiation is reciprocally inhibited (9) ; therefore, increased Th1 polarization is important for the control of asthma. Dendritic cells (DCs) are the most impor tant antigen-presenting cells; they are able to present antigens to naïve CD4 + T cells, and mediate their activation and differentiation (10) . In the pulmonary system, DCs predominantly exist in the bronchial epithelium, subepithelial tissue and bronchial lymph nodes, where they exhibit a grid-like distribution. DCs cluster with T cells in the subepithelial tissue and finely orchestrate the polarization of Th cells, which serves a key role in the regulation of inflammation and airway tolerance (11, 12) . It has previously been reported that following injection of ovalbumin (OVA) into the airway, DCs can activate naïve CD4 + T cells surrounding the pulmonary lymph nodes to a Th2 phenotype, thus inducing asthma (13) . The release of IL-12 from DCs has a central role in the induction of Th1 cell differentiation and IL-12-dependent DC-induced Th1 cell differentiation may suppress murine asthma (14, 15) . Decreased IL-12 levels are involved in Th2 polarization and are associated with the severity of asthma (16) . CD38, which consists of 304 amino acids, is a single chain type 2 transmembrane glycoprotein that belongs to the multifunctional ectoenzyme family (17, 18) . CD38 is expressed in several types of cells, including T cells, B cells and monocytes (19, 20) . Furthermore, as a multifunctional ectoenzyme, CD38 possesses numerous immunologically relevant functions. For example, CD38 participates in T-cell activation, B-cell growth and prevents apoptosis of tonsillar germinal center B cells (21) . Compared with wild type mice, the splenocytes from CD38-knockout mice were shown to secrete reduced interferon (IFN)-γ and increased IL-4, thus suggesting that CD38 has a role in Th1 polarization (22) . In addition, it has been reported that CD38 expression fluctuates during differentiation of human monocyte-derived DCs. CD38 was downregulated during differentiation into immature monocyte-derived DCs, whereas expression was restored upon maturation. When CD38 signaling was suppressed, monocyte-derived DCs exhibited a more immature phenotype and a reduced ability to present antigens and produce IL-12 (23) .
Due to the key role of IL-12 in the polarization of Th1 cells, the present study aimed to determine whether overexpression of CD38 in DCs was able to improve IL-12 production and Th1 cell polarization. Furthermore, the effects of CD38 overexpression in DCs on asthma development were determined.
Materials and methods
Reagents. Recombinant mouse granulocyte macrophage colony-stimulating factor (rmGM-CSF) and IL-4 were purchased from PeproTech (Rocky Hill, NJ, USA). Mouse Naïve CD4 + T cell Isolation kit was obtained from Miltenyi Biotec GmbH (Bergisch Gladbach, Germany). Anti-mouse IL-4 (BE0045) antibodies were purchased from Bio X Cell (West Lebanon, NH, USA). Anti-mouse major histocompatibility complex class II (MHC-II) (107607), anti-mouse CD80 (104707), anti-mouse CD86 (105007) and anti-mouse CD40 (124609) antibodies were purchased from Biolegend (San Diego, CA, USA). Anti-mouse CD38 (90), anti-mouse CD4 (17- . Mice were maintained in specific pathogen-free facilities with temperature ranging from 22-24˚C, humidity ranging from 50-60% and 12 h of light/dark cycle at Zhejiang University (Hangzhou, China). Mice had free access to food and water and were sacrificed by intraperitoneal injection with nembutal (160 mg/kg; Sigma-Aldrich; Merck Millipore). All experiments using mice were approved by and performed according to the guidelines of the Animal Ethics Committee of Zhejiang University.
Construction of recombinant mouse CD38 adenovirus (Ad-CD38
). Ad-CD38 was constructed using the AdMax™ system (Microbix Biosystems, Inc., Mississauga, OR, Canada). Briefly, the DNA fragment for murine CD38 was amplified from the splenocytes (1x10 6 cells) of C57BL/6 mice by polymerase chain reaction (PCR) using the following specific primers: Sense, 5'-GGG GTA CCT TCG GGA GCC CAA TGG CTAA-3' and antisense, 5'-GCT CTA GAA GTC CAG GCT ACA GGT GAT CTAA-3'. The primers were synthesized by Sangon Biotech (Shanghai) Co., Ltd. (Shanghai, China). The PCR was performed under the following conditions: 5 min at 94˚C; 30 cycles for 45 sec at 94°C, 45 sec at 55°C, and 90 sec at 72°C, and ended with 10 min at 72°C. The CD38 sequence was subsequently inserted into a pDC315 shuttle vector (BioVector, Beijing, China) and then 5 µg pDC315 vector was mixed with 5 µg pBHGloxΔE1, 3Cre Ad backbone plasmid (BioVector), 10 µl Lipofectamine 2000 (Thermo Fisher Scientific, Inc.). The mixture was transfected into HEK293 cells (American Type Culture Collection, Manassas, VA, USA). Approximately 10-15 days later, the cells floated and were collected in 1 ml phosphate-buffered saline (PBS). Then the cells were subjected to 3 cycles of freeze-thaw and the cell debris was removed by centrifugation (12,000 x g for 15 min). The supernatants were then rich in Ad-CD38, and were stored at -80˚C until further use.
Generation of bone marrow-derived DCs (BMDCs) and Ad infection.
After removing all muscle tissues with gauze from the femurs and tibias, the bones were placed in a 60-mm dish with 70% alcohol for 1 min, washed twice with PBS, and transferred into a fresh dish with RPMI 1640. Both ends of the bones were cut with scissors in the dish, and then the marrow was flushed out using 2 ml RPMI 1640 with a syringe and 25-gauge needle. The tissue was suspended, passed through nylon mesh to remove small pieces of bone and debris, and red cells were lysed with ammonium chloride. Then the bone marrow mononuclear cells were cultured at a density of 2x10 6 cells/ml in RPMI 1640 medium supplemented with 10% fetal calf serum (Thermo Fisher Scientific, Inc., Waltham, MA, USA), 10 ng/ml rmGM-CSF and 1 ng/ml IL-4 at 37˚C. Non-adherent cells were gently washed away after 48 h of culture; the remaining loosely adherent clusters were cultured for a further 48 h and were harvested for Ad transduction. For Ad infection, 1x10 6 BMDCs were mixed with 5x10 7 PFU Ad in a total volume of 1 ml serum-free medium for 24 h.
Fluorescence-activated cell sorting (FACS) analysis.
To confirm CD38 expression, Ad-infected BMDCs were stained with anti-CD38 at 4˚C for 20 min. Ad-infected BMDCs were stimulated with or without 100 ng/ml LPS for 24 h at 37˚C. The BMDCs were then collected and stained with MHC-II, CD80, CD86 and CD40 antibodies at 4˚C for 20 min. The non-specific binding of BMDCs and antibodies was determined by isotype control antibodies staining at 4˚C for 20 min. For the induction of Th1 cell differentiation, CD4
+ naïve T cells from splenocytes were purified using the Mouse Naïve CD4 + T cell Isolation kit according to the manufacturers instructions. Subsequently, 2x10 6 /ml naïve CD4 + T cells were seeded into 1 µg/ml anti-CD3 (BE0002; Bio X Cell) and 1 µg/ml anti-CD28 (BE0015-1; Bio X Cell) pre-coated 96-well plates in the presence of 10 µg/ml anti-IL-4. Ad-CD38-infected BMDCs (Ad-CD38/BMDCs), Ad-LacZ-infected BMDCs (Ad-LacZ/BMDCs) or equal volume PBS-treated BMDCs (Control/BMDCs) were added at a ratio of 10:1. Ad-LacZ was donated by Dr Zhijian Cai (Zhejiang University). CD4 + naïve T cells co-cultured with each group of BMDCs without anti-CD3 and anti-CD28 stimulation were designated as Th0 cells. After 3 days of induction at 37˚C, the cells were collected and stimulated with phorbol 12-myristate 13-acetate/ionomycin for 5 h. The cells were then stained with anti-CD4 antibody at 4˚C for 20 min, were fixed and permeabilized using the Intracellular Fixation & Permeabilization Buffer set, and were stained with anti-IFN-γ antibody at 4˚C for 20 min. All cells were examined by flow cytometry, and data were analyzed using the FlowJo software, version 7.6 (FlowJo, LLC, Ashland, OR, USA).
Quantitative (q)PCR. Th1 cells were induced as aforementioned. After 3 days of coculture with BMDCs, CD4 + T cells were sorted and total RNA was extracted from the CD4 + T cells using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The RNA was then reverse transcribed into cDNA using ReverTra Ace qPCR RT Kit (FSQ-101; Toyobo Co., Ltd., Osaka, Japan) according to the manufacturer's protocol and the qPCR was performed using SYBR Premix Ex Taq (RR420A; Takara Bio, Inc., Kusatsu, Japan) in a final volume of 20 µl according to the manufacturer's protocol. The specific primers synthesized by Sangon Biotech (Shanghai) Co., Ltd. used for qPCR were: β-actin, sense 5'-CGT TGA CAT CCG TAA AGA CC-3' , antisense 5'-AAC AGT CCG CCT AGA AGC AC-3'; T-bet, sense 5'-AGC AAG GAC GGC GAA TGTT-3', antisense 5'-GGG TGG ACA TAT AAG CGG TTC-3'; and IFN-γ, sense 5'-AGC GGC TGA CTG AAC TCA GAT TGT AG-3' and antisense 5'-GTC ACA GTT TTC AGC TGT ATA GGG-3'. The following PCR conditions were used: 1 cycle at 95˚C for 30 sec, followed by 40 cycles at 95˚C for 5 sec and 60˚C for 34 sec. qPCR was performed using an Applied Biosystems 7500 Real Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The relative mRNA levels of the target gene were calculated by the following formula: 2(Ct of target gene -Ct of β-actin). The relative mRNA levels were normalized by the relative mRNA level of one sample from the Control/BMDCs + LPS group.
Protocol for the model of allergen-challenged mice. Mice were sensitized on days 0 and 14 by intraperitoneal injection of 0.08 mg OVA and 0.1 ml aluminum hydroxide in 0.1 ml PBS or PBS alone. A total of 1x10 6 Ad-infected BMDCs were intravenously injected into the OVA-sensitized mice on day 23. Subsequently, OVA-or PBS-sensitized mice were exposed to aerosolized 1% OVA/0.01% LPS/PBS or normal saline for 40 min, respectively, once per day for 3 consecutive days (days 24-26). On day 27, the mice were sacrificed by intraperitoneal injection with nembutal (160 mg/kg) and the lungs were divided into two groups for analysis: The left lung lobes were lavaged three times with 1 ml PBS containing 1% fetal calf serum and 5 U/ml heparin, and the right lung lobes were fixed with 4% paraformaldehyde for hematoxylin (0.5%; 5 min) and eosin (1%; 30 sec) and Periodic acid (0.1%; 10 min) and Schiff (0.5%; 10 min) Schiff staining. Imaging was conducted using the BX53 microscope (Olympus Corporation, Tokyo, Japan).
Cytokine assays. Ad-infected BMDCs were stimulated with or without 100 ng/ml LPS for 24 h. To collect sera, mice were anesthetised by intraperitoneal injection with nembutal (80 mg/kg). Blood was exsanguinated from the heart with a syringe and 25-gauge needle and sera were collected after incubation at room temperature for 30 min. IL-12 levels in the supernatant were detected by ELISA. The levels of IL-4, IL-5, IL-13 and IFN-γ in the bronchoalveolar lavage fluid (BALF), and the levels of IgE in the sera were also detected by ELISA. Th1 cells were induced as aforementioned. After 3 days of coculture with BMDCs, CD4 + T cells were sorted and re-stimulated with 1 µg/ml anti-CD3 and 1 µg/ml anti-CD28 (pre-coated onto plates) for 24 h. Subsequently, the levels of IFN-γ in the supernatant were measured by ELISA. All ELISA assays were conducted according to manufacturer's instructions.
Western blot analysis.
For the detection of p-p38, Ad-infected BMDCs were stimulated with 100 ng/ml LPS for the indicated duration. Subsequently, the cells were washed and lysed by RIPA lysis buffer (Beyotime Institute of Biotechnology, Haimen, China). The protein concentrations of lysates were measured by the Bradford assay kit (Thermo Fisher Scientific, Inc.). Cell proteins (20 µg) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and were transferred onto polyvinylidene difluoride membranes. Membranes were blocked by Tris-buffered saline with Tween-20 containing 5% bovine serum albumin (Sigma-Aldrich; Merck Millipore) at room temperature for 2 h and then incubated with p-p38 (1:1,000) and p38 (1:1,000) primary antibodies at room temperature for 1 h, followed by horseradish peroxidase-coupled secondary antibody (sc-2005; 1:500) at room temperature for 1 h. Specific bands on the membrane were then visualized using an enhanced chemiluminescence (ECL) kit (ECL Detection kit; Amersham Biosciences; GE Healthcare Life Sciences, Little Chalfont, UK).
Statistical analysis. Data are presented as the mean ± standard error of the mean. The significance of differences between groups was estimated using the unpaired Student's t-test for two groups, or one-way analysis of variance followed by the Newman-Keuls test for multiple group comparisons. GraphPad Prism softtware, version 5 (GraphPad, Inc., La Jolla, CA, USA) was used for statistical analysis. P<0.05 was considered to indicate a statistically significant difference.
Results

CD38 promotes LPS-induced maturation of DCs and IL-12
secretion. The number of natural DCs is very limited, therefore, BMDCs are widely used for study of DC function in vitro and in vivo. CD38 was overexpressed in BMDCs following Ad-CD38 infection. To confirm the optimal multiplicity of infection (MOI), BMDCs were infected with Ad-CD38 at the following MOI: 10, 25, 50 and 100. A total of 24 hours after infection, CD38 expression was detected in BMDCs by FACS. As MOI increased, CD38 expression in BMDCs was elevated. However, there was no difference in CD38 expression between BMDCs infected with an MOI of 50 or 100 (Fig. 1A) . Therefore, for subsequent experiments, MOI 50 was selected for BMDC infection. Subsequently, CD38 expression was compared between Ad-CD38/BMDCs, Ad-LacZ/BMDCs or Control/BMDCs. The results demonstrated that Ad-CD38/BMDCs, but not Ad-LacZ/BMDCs or Control/BMDCs, exhibited increased CD38 expression (Fig. 1B) . By detecting the expression levels of MHC-II, CD80, CD86 and CD40 molecules, overexpression of CD38 was not able to affect DC maturation. However, following LPS stimulation, a more (Fig. 1C) . The levels of IL-12 in Ad-CD38/BMDCs, Ad-Lac Z/BMDCs and Control/BMDCs were low and showed no difference without LPS stimulation (data not shown). Similarly, a higher production of IL-12 could only be detected in Ad-CD38/BMDCs following LPS stimulation (Fig. 1D) . These results suggest that CD38 synergizes with LPS to promote DC maturation and IL-12 secretion.
LPS-stimulated Ad-CD38/BMDCs promote Th1 differentiation.
Since Ad-CD38/BMDCs stimulated with LPS produced more IL-12, the present study aimed to determine whether Ad-CD38/BMDCs were more effective at inducing Th1 cell differentiation. Naïve CD4 + T cells were isolated using the Naïve CD4 + T cell Isolation kit, and the purity of naïve CD4 + T cells was ~95% ( Fig. 2A) . Naïve CD4 + T cells were cocultured with BMDCs at a ratio of 10:1 for 3 days in Th1 cell-skewing conditions; with the exception of IL-12. (Fig. 2B and C) . To further confirm these results, IFN-γ Figure 3 . Administration of Ad-CD38/BMDCs can alleviate the severity of murine asthma. Mice were sensitized with PBS or OVA plus aluminium hydroxide on days 0 and 14. On day 23, 1x10 6 Control/BMDCs, Ad-LacZ/BMDCs or Ad-CD38/BMDCs were intravenously injected into OVA-sensitized mice (6 mice/group). The mice were then challenged with aerosolized PBS containing 1% OVA and 0.01% LPS (OVA-sensitized mice) or challenged with aerosolized NS (PBS-sensitized mice) for 3 consecutive days (days [24] [25] [26] . Mice were sacrificed 24 h after the last challenge and the lungs were isolated. (Fig. 2D) . These results indicate that LPS-stimulated Ad-CD38/BMDCs exhibit a higher potential for inducing Th1 cell differentiation.
Ad-CD38/BMDCs can alleviate the severity of murine asthma. To determine whether Ad-CD38/BMDCs exert protective effects on murine asthma, 1x10 6 Ad-infected BMDCs were intravenously injected into OVA antigen-immunized mice 24 h prior to the first OVA antigen challenge. After three OVA challenges, the recipients of Control/BMDCs, Ad-LacZ/BMDCs and Ad-CD38/BMDCs all developed airway inflammation, which was characterized by goblet cell hyperplasia, peribronchovascular eosinophilic infiltration, increased production of mucus, and a large number of total cells and eosinophil fractions in the BALF (Fig. 3A and  B) . However, the recipients of Ad-CD38/BMDCs exhibited the mildest symptoms of asthma (Fig. 3A and B) . In addition, production of IL-4, IL-5 and IL-13 was increased in the BALF, increased IgE was detected in the sera, and production of IFN-γ was reduced in the BALF of recipients of Control/BMDCs and Ad-LacZ/BMDCs (Fig. 3C) . These results suggest that Ad-CD38/BMDCs may inhibit asthma development in vivo, probably through regulating the Th1/Th2 cell balance.
CD38 is dependent on the p38 signaling pathway to promote LPS-induced BMDCs to release IL-12 and induce Th1 differentiation.
It has previously been reported that activation of the p38 signaling pathway is involved in IL-12 secretion by macrophages (24) . The present study determined whether CD38 promoted LPS-induced BMDCs to secrete IL-12 via the p38 signaling pathway. Following LPS stimulation, the expression levels of p-p38 were increased in Control/BMDCs, Ad-LacZ/BMDCs and Ad-CD38/BMDCs; the biggest increase was detected in Ad-CD38/BMDCs (Fig. 4A) . To further confirm the p38 signaling pathway was associated with increased IL-12 production in LPS-stimulated Ad-CD38/BMDCs, BMDCs were pre-treated with a p38-specific inhibitor, SB203580. The results demonstrated that there was no significant (Fig. 4B) . However, following pretreatment of BMDCs with SB203580, IL-12 secretion was decreased and the increased induction of Th1 cell differentiation by Ad-CD38/BMDCs was abrogated ( Fig. 4B and C) . These results suggest that LPS-stimulated Ad-CD38/BMDCs depend on the p38 signaling pathway to promote IL-12 production and Th1 cell differentiation.
Discussion
It is well known that a dysregulated Th1/Th2 balance is the predominant mechanism underlying asthma development. The present study demonstrated that overexpression of CD38 synergized with LPS to induce IL-12 secretion from BMDCs and Th1 differentiation. CD38-overexpressing BMDCs were effective at alleviating the severity of asthma, which was accompanied by a decrease in the Th2 master cytokine IL-4, and an increase in the Th1 master cytokine IFN-γ in the BALF of asthmatic mice. These results suggested that CD38 may be involved in the regulation of asthma development via its effects on the Th1/Th2 balance. Consistent with the results of a previous study, CD38 is able to synergize with LPS to induce IL-12 secretion from DCs (25) . However in this previous study, the authors did not elucidate whether activation of the CD38 signal alone could promote IL-12 secretion from DCs. According to the results of the present study, the CD38 signal alone exhibited no effect on IL-12 secretion of DCs. The CD38 signal is more inclined to regulate LPS-induced signal activation in DCs, particularly via the p38 signaling pathway. As LPS is the natural ligand for Toll-like receptor (TLR) 4 (26) , it is suggested that there is a point of intersection between TLR4 signaling and the CD38 signal. Unlike in vitro results, administration of Ad-CD38/BMDCs, without LPS stimulation, was able to alleviate asthmatic symptoms in vivo. The TLR4 signal in DCs has been reported to be activated in asthmatic mice (27) . TLR4 signaling in Ad-CD38/BMDCs may also be activated in asthmatic mice, and CD38 signaling may possibly further promote activation of TLR4 signaling in Ad-CD38/BMDCs. CD31 is a platelet endothelial cell adhesion molecule, which is a member of the immunoglobulin superfamily and is considered the counter-receptor of CD38. DCs express CD31 and CD38 at the same time (data not shown), so they may activate CD38 signal by themselves. In addition, CD31 has been demonstrated to be overexpressed in endothelial cells (28, 29) , suggesting CD38 signals in DCs may also be activated by endothelial cells. Therefore, it is reasonable to suggest that CD38 signaling in DCs is easily activated in vivo, thus indicating the important function of CD38 in DCs.
In conclusion, the present study demonstrated that overexpression of CD38 in BMDCs was able to increase LPS-induced IL-12 secretion and promote Th1 cell differentiation in a p38 signaling pathway-dependent manner. CD38-overexpressing BMDCs exhibited protective effects on murine asthma, potentially via restoration of the Th1/Th2 balance. Therefore, CD38 may be considered a promising candidate for the treatment of asthma.
